Close

Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data from Phase 2 “Evidence of Effect” Trial in Claudication Confirm the Rapid Effect of CK-357 Jun 3, 2011 08:01AM
Needham & Company maintains a 'Hold' on Cytokinetics (CYTK); Outlines Plans for Product Pipeline Apr 28, 2011 09:13AM
Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); CK-357 Data in ALS Encouraging, And We Await Study Findings in PVD and MG Feb 15, 2011 07:29AM
Needham & Company on Cytokinetics (CYTK): Phase 2a Data Show Potential of CK-357 to Improve Function in ALS Patients, and Phase 2 Multiple Dose Proof of Concept Planned Dec 13, 2010 01:15PM
Needham & Co Downgrades Cytokinetics (CYTK) to Hold; Lack of Near Term Catalysts Oct 29, 2009 10:55AM